ArticleIndian journal of microbiology2014
Azithromycin Reduces the Production of α-hemolysin and Biofilm Formation in Staphylococcus aureus.
Article in Indian journal of microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 66 citations in OpenAlex.
- A semi-solid in vitro biofilm model for evaluating antimicrobial potency and biofilm-specific activity.Biofilm · 2025Article
- Counteracting methicillin resistant Staphylococcus aureus through novel Citral-Azithromycin combination.Scientific reports · 2025Article
- DisarmingPathogens (Basel, Switzerland) · 2025Review
- Development and Evaluation of Azithromycin-Loaded Transethosomes for Enhanced Dermal Delivery and Antibacterial Efficacy.Pharmaceutics · 2025Article
- Evaluation of Quinazolin-2,4-Dione Derivatives as Promising Antibacterial Agents: Synthesis, In Vitro, In Silico ADMET and Molecular Docking Approaches.Molecules (Basel, Switzerland) · 2024Article
- Quorum Sensing Inhibitors: An Alternative Strategy to Win the Battle against Multidrug-Resistant (MDR) Bacteria.Molecules (Basel, Switzerland) · 2024Review
- Deciphering the crosstalk between inflammation and biofilm in chronic wound healing: Phytocompounds loaded bionanomaterials as therapeutics.Saudi journal of biological sciences · 2024Review
- Sub-MIC streptomycin and tetracycline enhancedBiofilm · 2023Article
- Recent advances in nanoantibiotics against multidrug-resistant bacteria.Nanoscale advances · 2023Review
- Synthesis of novel antibacterial nanocomposite CuO/Ag-modified zeolite for removal of MB dye.Scientific reports · 2023Article
- Delving into the Mechanisms of Sponge-AssociatedMolecules (Basel, Switzerland) · 2023Article
- It is the time for quorum sensing inhibition as alternative strategy of antimicrobial therapy.Cell communication and signaling : CCS · 2023Review
- Inhibition of Staphylococcus aureus Biofilm Formation and Virulence Factor Production by Petroselinic Acid and Other Unsaturated C18 Fatty Acids.Microbiology spectrum · 2022Article
- Celastrol mitigates staphyloxanthin biosynthesis and biofilm formation in Staphylococcus aureus via targeting key regulators of virulence; in vitro and in vivo approach.BMC microbiology · 2022Article
- Azithromycin-loaded linolenic acid-modified methoxy poly(ethylene glycol) micelles for bacterial infection treatment.Drug delivery and translational research · 2022Article
- Review
- Responses to chemical cross-talk between the Mycobacterium ulcerans toxin, mycolactone, and Staphylococcus aureus.Scientific reports · 2021Article
- Antibiofilm Activity of Phorbaketals from the Marine SpongeMarine drugs · 2021Article
- Factors Affecting Bacterial Adhesion on Selected Textile Fibres.Indian journal of microbiology · 2021Article
- The Role of Subinhibitory Concentrations of Daptomycin and Tigecycline in Modulating Virulence inAntibiotics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Staphylococcus aureus causes a broad range of life-threatening diseases in humans. This bacterium produces a large number of extracellular virulence factors that are closely associated with specific diseases which are controlled by quorum sensing. In this study, we show that azithromycin was active against methicillin-resistant Staphylococcus aureus (MRSA) strains with MICs ranged from 32 to 64 μg/mL. Azithromycin at subinhibitory concentration, markedly reduced the production of α-hemolysin at (1/16MIC, 1/8MIC) and biofilm formation at (1/16MIC, 1/8MIC), respectively. The results indicated that sub-inhibitory concentrations of azithromycin decreased the production of α-hemolysin and biofilm formation in MRSA in a dose-dependent manner. Therefore, azithromycin may be useful in the treatment of α-hemolysin producing and biofilm formation MRSA infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.